Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 147.85 INR
Change Today +1.10 / 0.75%
Volume 247.0K
As of 7:06 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

venus remedies ltd (VNR) Snapshot

Open
147.75
Previous Close
146.75
Day High
154.50
Day Low
145.90
52 Week High
09/15/14 - 381.75
52 Week Low
03/23/15 - 95.60
Market Cap
1.7B
Average Volume 10 Days
174.3K
EPS TTM
4.51
Shares Outstanding
11.4M
EX-Date
09/23/14
P/E TM
32.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for VENUS REMEDIES LTD (VNR)

Related News

No related news articles were found.

venus remedies ltd (VNR) Related Businessweek News

No Related Businessweek News Found

venus remedies ltd (VNR) Details

Venus Remedies Limited manufactures and trades in medicines in India and internationally. Its product portfolio includes approximately 75 products in various therapeutic segments comprising anti-cancer, anti-infective, neurology, emergency care medicine, skin and wound care, and pain management. The company offers its products under the Mebatic, Calridol, Moximicin, Neurotol, Glutapep, Elores, Vancoplus, Potentox, Tobracef, Supime, Zydotum, Pirotum, Ronem, Lastinem, Fejet, Actimycin, Megaparin, Taxedol, Paclitol, Oxol, Citabol, Carplat, and other names. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Founded in 1989

venus remedies ltd (VNR) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: 6.1M
Joint Managing Director, Head of Venus Medici...
Total Annual Compensation: 5.3M
Whole Time Director and Chief Executive Offic...
Total Annual Compensation: 2.9M
Executive Director of Marketing, Executive Di...
Total Annual Compensation: 3.2M
Compensation as of Fiscal Year 2014.

venus remedies ltd (VNR) Key Developments

Venus Remedies Ltd., Board Meeting, Jun 30, 2015

Venus Remedies Ltd., Board Meeting, Jun 30, 2015. Agenda: To issue fully convertible warrants/equity shares to promoters on a preferential basis subject to approval in the general meeting; to fix the date of annual general meeting; to consider any other business with permission of the Chair.

Venus Remedies Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Year and Consolidated Earnings Results for the Year Ended March 31, 2015

Venus Remedies Ltd. reported audited standalone earnings results for the fourth quarter and year and consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported total Income from operation (net) of INR 988.81 million compared to INR 1,423.43 million, loss from operations before other income, finance costs and exceptional items of INR 52.32 million compared to profit from operations before other income, finance costs and exceptional items of INR 237.47 million, loss from ordinary activities before tax of INR 206.60 million compared to profit from ordinary activities before tax of INR 165.91 million and net loss of INR 206.60 million or INR 18.06 per basic share compared to net profit of INR 141.09 million or INR 12.33 per basic share for the last year. For the year, on standalone basis, the company reported total Income from operation (net) of INR 4,518.75 million compared to INR 5,260.55 million, profit from operations before other income, finance costs and exceptional items of INR 421.92 million compared to INR 946.19 million, profit from ordinary activities before tax of INR 20.35 million compared to INR 657.32 million and net profit of INR 45.48 million or INR 3.97 per basic share compared to INR 609.50 million or INR 54.19 per basic share for the last year. For the year, on consolidated basis, the company reported total Income from operation (net) of INR 4,639.91 million compared to INR 5,415.56 million, profit from operations before other income, finance costs and exceptional items of INR 431.82 million compared to INR 980.10 million, profit from ordinary activities before tax of INR 26.48 million compared to INR 690.78 million and net profit of INR 51.61 million or INR 4.52 per basic share compared to INR 642.96 million or INR 57.11 per basic share for the last year.

Venus Remedies Ltd. to Report Q4, 2015 Results on May 30, 2015

Venus Remedies Ltd. announced that they will report Q4, 2015 results on May 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNR:IN 147.85 INR +1.10

VNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNR.
View Industry Companies
 

Industry Analysis

VNR

Industry Average

Valuation VNR Industry Range
Price/Earnings 22.1x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 2.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENUS REMEDIES LTD, please visit www.venusremedies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.